Irregular Periods: Drugs That Cause or Treat It, and What Your Cycle Is Really Telling You

What Counts as an Irregular Period?

A period is irregular when your cycle length varies by more than 7-9 days from cycle to cycle, your bleeding lasts fewer than 2 days or more than 7 days, or you bleed more than 80 mL per period. Cycles shorter than 21 days (polymenorrhea) or longer than 35 days (oligomenorrhea) also fall outside normal range, and the complete absence of periods for three or more months in a woman who was previously cycling is called secondary amenorrhea.

Your menstrual cycle is not just a reproductive event. The American College of Obstetricians and Gynecologists classifies the menstrual cycle as a vital sign, meaning persistent irregularity signals a systemic problem worth investigating rather than a nuisance to suppress without inquiry.

What "Normal" Looks Like Across Life Stages

Cycle regularity is not static. During the first two to three years after your first period (menarche), cycles of 21-45 days are considered normal because the hypothalamic-pituitary-ovarian (HPO) axis is still maturing. From roughly ages 20-40, cycles typically stabilize in the 24-35 day range. During perimenopause, which begins on average four to eight years before the final period, cycle length variability increases again, with some cycles becoming shorter and others dramatically longer as follicle-stimulating hormone (FSH) rises and ovarian reserve declines.

Postpartum, it is normal for ovulatory cycles to take six to twelve weeks to resume if you are not breastfeeding, and up to eighteen months or longer if you are exclusively breastfeeding, due to prolactin-mediated suppression of GnRH.

Why Your Periods Are Irregular: The Most Common Causes

Irregular periods arise from disruption at any point in the HPO axis, from the uterine lining itself, or from systemic hormonal or metabolic disease. The most clinically useful categories are hormonal, structural, medication-related, and lifestyle-related.

Hormonal and Metabolic Causes

PCOS is the single most common endocrine cause of irregular cycles in reproductive-age women, affecting 8-13% of women worldwide. Anovulation or oligo-ovulation is its defining reproductive feature, producing cycles that can range from 35 days to several months apart, or no cycles at all.

Thyroid dysfunction is the second most commonly missed hormonal cause. Both hypothyroidism and hyperthyroidism disrupt menstrual regularity. Subclinical hypothyroidism, defined as TSH above 4.5 mIU/L with normal free T4, is present in roughly 5-10% of women and can cause oligomenorrhea, heavy bleeding, or both, even without classic fatigue symptoms.

Hyperprolactinemia raises prolactin enough to suppress GnRH pulsatility, causing oligomenorrhea or amenorrhea. Causes include prolactinomas, hypothyroidism, and several common medications (see below). Measuring serum prolactin is a standard part of the irregular-periods workup.

Hypothalamic amenorrhea (HA) results from energy deficit, excessive exercise, or psychological stress suppressing GnRH. It is common in female athletes and women with restrictive eating patterns. Bone loss accelerates in HA because estrogen drops sharply, and ACOG recommends calcium 1,000-1,300 mg daily and vitamin D 600-800 IU for women with HA to partially offset bone loss while the underlying cause is addressed.

Perimenopause begins with subtle cycle shortening (often to 23-25 days) and progresses to erratic variation of 7 days or more. The STRAW+10 staging system classifies menopausal transition stages by cycle variability and FSH, and remains the clinical standard for defining where a woman is in the perimenopausal continuum.

Structural Causes

Fibroids, endometrial polyps, adenomyosis, and endometriosis can all cause irregular or heavy bleeding. These are anatomic problems requiring imaging (usually transvaginal ultrasound as a first step, sometimes with saline infusion sonography or hysteroscopy) to diagnose. Drug therapy alone rarely resolves them definitively.

Drugs That Cause Irregular Periods

Several medication classes reliably disrupt menstrual cycles. If you started a new drug and your periods changed within one to three cycles, medication effect is high on the differential.

Hormonal Contraceptives

Hormonal contraceptives are both the most common cause and the most common treatment of irregular bleeding, depending on the formulation. Breakthrough bleeding (unscheduled bleeding on a hormonal method) affects 20-40% of women in the first three months of combined oral contraceptive (OC) use. Progestin-only pills (the minipill) cause irregular spotting in approximately 40% of users, and the 52 mg levonorgestrel IUD (Mirena) causes irregular light bleeding for the first 3-6 months before most users develop amenorrhea.

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) causes irregular, unpredictable bleeding in the first year of use in most women, with 50% of users becoming amenorrheic by 12 months. Return to regular ovulatory cycles after stopping DMPA can take 9-18 months.

Antipsychotics and Antidepressants

Antipsychotics that block dopamine D2 receptors raise prolactin levels substantially. Risperidone and haloperidol are among the highest-prolactin-raising agents, causing amenorrhea or oligomenorrhea in a significant proportion of women who take them at therapeutic doses. Olanzapine and quetiapine raise prolactin less. If you are on an antipsychotic and your periods have stopped, ask your prescriber to check a serum prolactin before assuming the cause is something else.

SSRIs and SNRIs have a weaker effect on prolactin but can cause cycle changes in some women, particularly at higher doses. The evidence is less clear than for antipsychotics.

Other Medications That Disrupt Cycles

| Drug or Drug Class | Mechanism | Typical Effect on Cycle | |---|---|---| | Antipsychotics (risperidone, haloperidol) | Dopamine blockade raises prolactin | Oligomenorrhea, amenorrhea | | Valproate / valproic acid | Raises androgens, may induce PCOS-like state | Irregular, heavy bleeding | | Chemotherapy agents | Gonadotoxic; may cause premature ovarian insufficiency | Oligomenorrhea to amenorrhea | | Thyroid medications (overreplacement) | Suppresses TSH, mimics hyperthyroidism | Short cycles, spotting | | Corticosteroids (chronic use) | Suppress HPO axis | Oligomenorrhea | | Opioids (chronic) | Suppress GnRH | Oligomenorrhea, amenorrhea | | GnRH agonists (leuprolide, nafarelin) | Downregulate HPO axis | Amenorrhea (intended) |

Valproate deserves particular attention in women of reproductive age. Several studies link valproate use to PCOS-like features, including polycystic ovaries, elevated androgens, irregular cycles, and weight gain, especially in women who start valproate before age 20. If you take valproate for epilepsy or bipolar disorder, ask your neurologist or psychiatrist to check androgens and a menstrual history at least annually.

Drugs That Treat Irregular Periods

The right pharmacological treatment depends on the diagnosis. Suppressing the cycle with a combined pill when the underlying cause is an undiagnosed prolactinoma, for example, delays appropriate care. Work with a clinician to establish the cause before choosing a drug.

For PCOS-Related Irregular Cycles

Combined oral contraceptives (COCs) remain the most widely used first-line treatment for cycle regulation in PCOS when contraception is also desired or the woman is not trying to conceive. They suppress LH, reduce ovarian androgen production, and induce predictable withdrawal bleeds. The Endocrine Society's 2023 PCOS guideline recommends COCs as first-line pharmacotherapy for menstrual irregularity in PCOS, noting no strong evidence for preferring one progestin over another for cycle control specifically.

Metformin reduces insulin resistance, lowers LH, and improves ovulatory frequency in women with PCOS and insulin resistance. A 2012 Cochrane review found metformin increases ovulation rates compared to placebo in women with PCOS (OR 3.88, 95% CI 2.25-6.69). The typical starting dose is 500 mg once or twice daily with food, titrated to 1,500-2,000 mg/day. Gastrointestinal side effects are common on initiation but usually resolve within four to six weeks; extended-release formulations reduce this.

Progestin-only withdrawal bleeding (for women not on regular contraception) is used in women with oligomenorrhea who need cycle protection against endometrial hyperplasia. Medroxyprogesterone acetate 10 mg daily for 10-14 days, or norethindrone 5 mg daily for the same duration, every one to three months induces a withdrawal bleed and provides endometrial protection. This is not a treatment of the underlying cause, but it protects the endometrium while the workup or lifestyle interventions are ongoing.

For Thyroid-Related Irregularity

Treating the thyroid disorder is the primary intervention. Levothyroxine, titrated to a TSH of 0.5-2.5 mIU/L for most premenopausal women, typically restores regular ovulatory cycles within two to four menstrual cycles once euthyroid status is achieved. The American Thyroid Association recommends TSH targets of 0.1-1.5 mIU/L during pregnancy, which means if you are actively trying to conceive and have thyroid-related cycle irregularity, your levothyroxine dose may need to be higher than what kept your cycles regular outside of pregnancy attempts.

For Hyperprolactinemia

Dopamine agonists, specifically cabergoline (0.25-0.5 mg twice weekly) and bromocriptine (2.5-7.5 mg/day), are the first-line medical treatment for hyperprolactinemia from a prolactinoma or idiopathic cause. Cabergoline normalizes prolactin in approximately 80% of patients with microprolactinomas and restores ovulatory cycles in most of those women within a few months of achieving normal prolactin levels. Cabergoline is generally better tolerated than bromocriptine. If a medication (antipsychotic, for example) is causing hyperprolactinemia, working with the prescribing clinician to switch to a lower-prolactin-raising agent is preferable when clinically safe.

For Perimenopausal Irregular Bleeding

Perimenopausal irregular and heavy bleeding is one of the most undertreated conditions in women's health. Options depend on whether contraception is also needed.

Low-dose combined OCs (20 mcg ethinyl estradiol formulations) regulate cycles, reduce heavy bleeding, and provide contraception in perimenopausal women who are not yet menopausal. They can be used until menopause is confirmed (FSH above 30 mIU/mL on two measurements, one year of amenorrhea) if there are no contraindications such as smoking, migraine with aura, or cardiovascular risk factors.

The 52 mg levonorgestrel IUD (Mirena) is a particularly effective option for perimenopausal heavy or irregular bleeding. A randomized trial published in the NEJM found the levonorgestrel IUD reduced menstrual blood loss by 97% at 12 months compared to usual care. It also provides endometrial protection if systemic estrogen is added for vasomotor symptoms.

Systemic menopausal hormone therapy (MHT) typically does not regulate cycles in perimenopause in the way COCs do. MHT is designed for postmenopausal symptom relief, not for cycle control during the transition. For cycle regulation in perimenopause, cyclical progestins or hormonal contraception are more appropriate.

For Hypothalamic Amenorrhea

Pharmacological treatment is rarely the first step in hypothalamic amenorrhea. The primary intervention is restoring energy availability through increased caloric intake, reduced exercise volume, and treatment of any underlying eating disorder. If bone loss is a concern and periods do not return within six to twelve months of weight and energy restoration, ACOG acknowledges that transdermal estrogen with cyclic progestin may be considered to reduce bone loss, though evidence that it fully restores bone density is limited.

Pregnancy and Lactation: What You Need to Know Before Starting Any Treatment

This section is required reading if there is any chance you are or could become pregnant.

Drugs That Treat Irregular Periods: Pregnancy Safety

| Drug | Pregnancy Safety | Lactation | Contraception Required? | |---|---|---|---| | Combined OCs | Contraindicated in confirmed pregnancy; not teratogenic in early inadvertent exposure per current data | Transfer to breast milk; not recommended in first 6 weeks postpartum | They ARE the contraception | | Medroxyprogesterone (oral) | Avoid in pregnancy; historical animal data showed teratogenicity; avoid use | Compatible with breastfeeding | Yes, if not on COC | | DMPA injection | Avoid in confirmed pregnancy | Compatible; may reduce milk supply in some women | It IS the contraception | | Metformin | Category B; widely used in PCOS during first trimester; ACOG notes insufficient evidence to recommend or avoid in first trimester for PCOS alone | Excreted in breast milk in low amounts; generally considered compatible | No, but check with your provider | | Cabergoline | Limited human data; generally discontinued once pregnancy confirmed for microprolactinoma; Endocrine Society recommends stopping once pregnancy is confirmed in most microprolactinoma cases | Avoid; suppresses lactation (it is a lactation inhibitor) | Yes | | Bromocriptine | More safety data in pregnancy than cabergoline; used when conception occurs on treatment | Suppresses lactation; avoid | Yes, unless intended as lactation suppression | | Levothyroxine | Safe in pregnancy; dose requirement increases by 25-30% | Safe | No | | Valproate | TERATOGENIC. Major neural tube defects, cognitive impairment. FDA Black Box Warning; REMS program required | Compatible but monitor infant | Reliable contraception is MANDATORY |

Valproate requires special emphasis. Women of childbearing potential taking valproate must use effective contraception. The drug causes neural tube defects, craniofacial abnormalities, and significant reductions in IQ in exposed children. If you are on valproate and wish to conceive, a planned transition to a safer antiepileptic or mood stabilizer with your neurologist or psychiatrist before conception is essential.

Trying to Conceive with Irregular Periods

If you have irregular periods and want to become pregnant, ovulation induction is usually needed. For PCOS, letrozole 2.5-5 mg on cycle days 3-7 is now first-line over clomiphene citrate, after the PPCOSII trial demonstrated higher live birth rates with letrozole (27.5% vs 19.1% per cycle). For hypothalamic amenorrhea, pulsatile GnRH via subcutaneous pump or gonadotropin injections are required because the HPO axis itself is suppressed.

Who This Is Right For, and Who Should Look for Other Answers

Life Stage Alignment

Adolescents (ages 12-21): Cycle irregularity in the first two years after menarche is usually normal axis maturation. If cycles have not established within three years of menarche, or if there are signs of androgen excess (acne, hirsutism), a PCOS workup is appropriate. ACOG recommends against labeling adolescent cycle variation as pathological within the first two to three years post-menarche.

Reproductive age (ages 21-40): New-onset irregularity here should prompt TSH, prolactin, free testosterone, DHEAS, and a pregnancy test before any pharmacological treatment is started.

Trying to conceive: Irregular cycles mean unpredictable or absent ovulation. Tracking with ovulation predictor kits (LH surge) becomes unreliable. Referral to a reproductive endocrinologist is appropriate if six months of timed intercourse has not resulted in conception (three months if you are 35 or older).

Perimenopause (typically ages 40-52): Cycle variability is expected but heavy bleeding, very frequent cycles, or intermenstrual bleeding still warrant endometrial evaluation, particularly if BMI is above 30 or there is a history of PCOS, since both raise endometrial cancer risk. ACOG recommends endometrial sampling in women 45 and older with abnormal uterine bleeding.

Postmenopause: Any vaginal bleeding more than 12 months after the final period requires evaluation to rule out endometrial pathology. This is not a gray zone.

Who Should Not Start Hormonal Treatment Without Further Workup

Do not start hormonal contraceptives to regulate cycles without excluding: undiagnosed pelvic mass, unexplained intermenstrual or postcoital bleeding, uncontrolled hypertension, personal or family history of estrogen-sensitive cancers, migraine with aura (for estrogen-containing methods), and active liver disease.

When to Seek Same-Week Evaluation

The following are not "wait and see" situations. Seek care within one week if you experience:

• Soaking more than one pad or tampon per hour for two or more consecutive hours
• Bleeding for more than 7 days continuously
• Passing clots larger than a quarter
• Periods that have stopped for more than three months and you are not pregnant, postpartum, or on a hormonal method that causes amenorrhea
• Intermenstrual or postcoital bleeding that is new
• Any vaginal bleeding if you are postmenopausal
• Cycle irregularity accompanied by galactorrhea (milky nipple discharge), which suggests hyperprolactinemia
• Signs of androgen excess: new hirsutism, clitoromegaly, or deepening voice (these need rapid-onset androgen excess ruled out)

The combination of irregular cycles with pelvic pain, painful sex, or infertility should prompt evaluation for endometriosis, which affects approximately 1 in 10 women of reproductive age and is delayed in diagnosis by an average of 7-10 years.

Evidence Gaps: What We Still Do Not Know

Women have been historically underrepresented in clinical trials studying menstrual cycle disorders. Most of the data on metformin for PCOS cycle regulation, for example, comes from trials in women with obesity and hyperinsulinemia, which means the evidence is thinner for lean women with PCOS. Similarly, the long-term effects of antipsychotic-induced amenorrhea on bone density in women have been studied far less rigorously than antipsychotic effects in men. The optimal duration of cabergoline treatment for prolactinoma-related cycle disruption specifically in perimenopausal women is not well-defined in the literature. Where these gaps exist, the treatment recommendations above reflect best-available extrapolation from related populations rather than direct study in the specified group.